Background: WHO grade II gliomas are often approached by radiation therapy (RT). However, little is known about tumor response and its potential impact on long-term survival. Patients and Methods: Patients subjected to RT were selected from the own database of WHO grade II gliomas diagnosed between 1991 and 2000. The volumetric tumor response after RT was assessed based on magnetic resonance imaging and graded according to standard criteria as complete, partial (PR, ≥ 50%), or minor (MR, 25% to < 50%). Results: There were 24 astrocytomas and three oligoastrocytomas. 21 patients (78%) were dead at follow-up (mean survival 74 months). None of the patients had chemotherapy. Objective response occurred in 14 patients (52%, five PR and nine MR) but was not associated with overall survival. The vast majority of the tumors had no loss of heterozygosity (LOH) 1p and/or 19q (86%).
Introduction
Radiation therapy (RT) is frequently used to treat adult patients with supratentorial WHO grade II gliomas [3, 6, 7, 10-12, 16, 20] . However, the impact of RT on overall survival is unclear and the data on the frequency, extent and predictive factors of objective tumor response after RT are almost inexistent for this group of patients [4, 25] . RT may be administered early after diagnosis (early radiation therapy [eRT] ) or when the tumor progresses (delayed radiation therapy [dRT] ). It was demonstrated that eRT improves progressionfree survival, but not overall survival, as compared with dRT [9, 21, 24, 25] .
Prognostic factors for progression-free and overall survival in WHO grade II glioma patients include young age, good neurologic and overall performance status, small preoperative tumor volume, lack of enhancement on imaging, oligodendroglial histology, and possibly gross total resection [19] . Loss of heterozygosity (LOH) 1p/19q, which is typically but not exclusively associated with an oligodendroglial morphology [1, 18, 22, 26] , is clearly emerging as a strong prognosticator of longer overall survival in this group of patients [14, 23, 24, 26] . Also, LOH 1p/19q is a strong predictor of response to chemotherapy [1, 2, 8, 23] and some data suggest that it may be a predictor of response to RT [1] .
In the present study, we analyzed tumor response after RT and long-term survival in a consecutive series of patients with WHO grade II gliomas diagnosed between 1991 and 2000. In these patients we also assessed whether the tumors had LOH 1p36/19q13 or not.
Patients and Methods
This was an observational, retrospective, single-center study where data on patients with WHO grade II treated at our institution between 1991 and 2000 were collected prospectively.
Clinical and Volumetric Data
From our database of WHO grade II glioma patients [14, 15] we selected those subjected to RT. The survival data were updated in March 2005 for all patients. None of the patients had received chemotherapy by that time [14] . Digitalized pre-RT and post-RT magnetic resonance images (MRIs) were interactively analyzed using a dedicated software (NIH Image for Macintosh by Wayne Rasband, modified for use with Windows, © 2000 Scion Corporation), as described [15] . Tumor volumes were measured based on the entire region of hyperintensity (compared to normal brain) in T2-weighted and FLAIR MRIs. Tumor response was assessed between 3 and 12 months after RT and defined as minor (MR, reduction by ≥ 25% to < 50% of the initial tumor volume), partial (PR, ≥ 50%), and complete (CR, no residual tumor) [13] . Progressive disease (PD) was defined as an increase in tumor volume by ≥ 25%. Patients with CR, PR and MR were defined as responders, patients with stable disease (SD) or PD as nonresponders.
Radiation Therapy
Our center recommends eRT for "high-risk" and dRT for "low-risk" patients [24] . High age (> 45 years), large residual tumor (> 5 cm cross sectional diameter or > 60 cm 3 ), bihemispheric involvement, midline shift, preoperative neurologic deficits, and a gemistocytic component were considered risk factors for early progression. In presence of two or more risk factors eRT was typically recommended. Delayed RT was performed at tumor progression, if the recurrent tumor was not considered operable. After CT based three dimensional planning, conformal RT was performed with a linear accelerator (6-MV or 15-MV photons) using multiple fields. 54-60 Gy were administered in daily fractions of 1.8-2 Gy to the tumor region and approximately 2 cm of the adjacent brain but a maximum dose of 52 Gy on the optic nerves.
LOH for Chromosomes 1p36 and 19q13
Tumor DNA was extracted from formalin-fixed, paraffin-embedded tissue. Reference (normal) DNA was isolated either from the patient's peripheral blood leukocytes or from tumor-free areas of paraffin-embedded specimens after careful microscopic analysis and subsequent dissection. Microsatellite markers for the chromosomal regions 1p36.21-1p36.33 (D1S468, D1S1612, D1S228, D1S214), and 19q13.31-19q13.41 (D19S219, D19S412, D19 HRC) were amplified by polymerase chain reaction, and analyzed for LOH, as described [14] .
Statistical Analysis
Patient and therapy-related factors were tested for a possible correlation with response after RT. Fisher's exact test based on cross-tables was performed to test the influence of age (≤ and > 40 years), gender, presence of any oligodendroglial component, presence of a gemistocytic component, 1p36 and 19q13 status, and tumor volume (≤ and > 70 cm 3 ). The impact of objective tumor response and of the timing of RT (eRT vs. dRT) on overall survival was analyzed using the unpaired t-test and Kaplan-Meier methods. The level of statistical significance was set at p < 0.05 for a two-tailed hypothesis. The software WinSTAT ® for Excel 2003 was used for this analysis.
Results

Cohort's Characteristics, Timing of Radiotherapy, and Overall Survival
Out of the 79 patients diagnosed with WHO grade II glioma between 1991 and 2000 at the University Hospital of Bern, Switzerland, 47 received RT. Preoperative, postoperative and follow-up MRI exams for assessment of tumor response and progression were available for 27 patients, who were the focus of the present study.
There were ten female and 17 male patients with a median age of 38 years (mean 42.5 ± 2.3 SEM [standard error of mean], range 26-67 years) at the time of diagnosis. The histo-logical diagnosis was oligoastrocytoma in three patients and astrocytoma in 24 patients. There was no oligodendroglioma. Early RT was performed in twelve patients after a mean of 4.5 months following diagnosis (range 0-12 months); four patients had three risk factors (see Patients and Methods), seven patients had two risk factors (mainly large residual tumors and age), and one patient requested RT (patient's choice). Delayed RT was administered in 15 patients after a mean of 38 months following diagnosis (range 18-72 months): 14 patients had tumor progression (with a new contrast enhancement in seven of them), one patient requested the treatment (patient's choice).
21 patients (78%) were dead at follow-up. The mean overall survival after diagnosis was 74 months (SEM 7.3, range 7-160 months). The mean follow-up of the six survivors was 113 months (range 62-160 months). None of the factors tested was found to be significantly associated with overall survival. However, male gender, dRT, and tumor volumes ≤ 70 cm 3 were positively associated with overall survival after diagnosis (Table 1) . There was also a trend for longer overall survival in the patients without any evidence of malignant transformation on MRI (p = 0.13 for overall survival from the time of diagnosis; p = 0.1 for overall survival from the time of RT).
Tumor Response, Predictive Factors, and Survival
Overall, 14 patients (five after eRT and nine after dRT) showed an objective tumor response (52%): a PR in five (18.5%) and an MR in nine patients (33%). 13 patients had either SD (ten patients) or PD (three patients). The mean tumor volume was 103 cm 3 (SEM 16.6, range 16.6-332 cm 3 ) before and 76.7 cm 3 (SEM 16.7, range 13-392 cm 3 ) after RT. The mean interval to maximum tumor reduction was 6 months after RT (SEM 0.7). Tumor regrowth was observed after a mean of 26 months (SEM 3.7). The graph plotting the changes of tumor volume over time after RT is shown in Figure 1 .
The LOH analysis for 1p or 19q was conclusive in 22 out of 27 patients (81.5%). Overall, only three patients (13.6%) had loss of either 1p (one patient), 19q (one patient), or both (one patient). Tumor response was observed in ten (52.6%) out of 19 patients without LOH 1p and/or 19q. Of the three patients with LOH of 1p and/or 19q, one had an MR and two an SD. The number of patients with LOH 1p36 and/or 19q13 (three patients) was insufficient to test an impact on response (Table 1) . The mean overall survival after diagnosis was longer for responders than for nonresponders (80 months ± 11 SEM vs. 67 months ± 9.4 SEM). However, the difference did not reach statistical significance (t-test, Mann-Whitney test). This finding was confirmed by the Kaplan-Meier analysis (Figure 2 ; p = 0.33). Also, the overall survival after RT (mean 51 months ± 6.3 SEM, range 7-117 months) was no different in responders and nonresponders (Figure 2 ; p = 0.9). Comparing the seven patients with MRI evidence of malignant transformation with those without this evidence did not reveal significant differences in terms of tumor response after RT (t-test, p = 0.8-0.9).
Discussion
To our knowledge, this is the first study analyzing objective tumor response in a cohort of adult patients with WHO grade II gliomas subjected to RT. A reduction in tumor volume after RT was observed in approximately 90% of the patients. The reduction in tumor volume met the criteria of an objective tumor response in 14 out of 27 patients (52%). Tumor response reached its maximum approximately 6 months after RT, a finding that matches well what has been reported for pediatric low-grade gliomas [4] .
A potential problem with our approach of measuring the tumor volume based on MRI [15] is that hyperintensity changes on T2-weighted and FLAIR images, especially in the long-term follow-up, can be side effects of radiation [5] . Even if postirradiation changes might interfere in the evaluation of tumor progression after RT in the long term, they should not influence the assessment of tumor response, which is characterized by a reduction of the T2-hyperintense, neoplastic regions relatively early after treatment.
None of the factors tested as potential predictors of tumor response were statistically significant. Bauman et al. suggested a positive association between LOH 1p and survival after RT in oligodendroglioma patients [1] . LOH 1p/19q was a rare event in our series, as expected since the vast majority of the tumors were astrocytomas [17, 18] . The low incidence of LOH 1p/19q prevented us from assessing its potential, positive predictive value for response to RT. However, we could show, that an objective tumor response after RT occurs in approximately half of the patients despite the absence of LOH 1p/19q. This finding may become important for patients' management in the future. The ongoing, cooperative, EORTC trial 22033, in which patients with WHO grade II supratentorial gliomas are stratified according to the 1p status and randomized to receive either RT or temozolomide has the potential for elucidating the predictive role of LOH 1p for RT in the future.
The lack of a significant survival advantage for responders over nonresponders is somewhat surprising in the present series. The relatively small number of patients is a possible explanation (type 1 error). However, the length of followup, with > 75% of the patients having died within that follow-up, and the absence of a trend for a longer overall survival after RT in the responders suggest the validity of this finding. In fact, the major determinant of overall survival in patients with WHO grade II gliomas is the occurrence of ma- lignant transformation, as suggested by the large cooperative study showing that RT can prolong the progression free survival but not the overall survival of WHO grade II glioma patients [25] . Even in a small series like ours, we found a clear trend for a shorter overall survival in patients with a "high-risk" profile for malignant transformation, that is in patients selected for eRT (n = 12) [25] and in patients with a new contrast enhancement before dRT (n = 7). Altogether, these data suggest that RT does not influence the cascade of events eventually leading to the malignant transformation of a WHO grade II glioma, which eventually determines overall survival.
Conclusion
We demonstrated that approximately half of the patients with a WHO grade II glioma show an objective response after RT, even in the absence of LOH 1p/19q. The impact of response to RT on overall survival and the factors predicting response to RT remain unclear.
Figures 2a and 2b. Kaplan-Meier curves of overall survival after RT (a) and after diagnosis (b) are shown for responders and nonresponders. Although a survival advantage after diagnosis is visible for the responders, it is not statistically significant (log-rank test, p = 0.33).
Abbildungen 2a und 2b. Die Kaplan-Meier-Kurven der Gesamtüberlebenszeit nach RT (a) und nach Diagnosestellung (b) für Responder und Nonresponder. Obwohl es für die Responder einen Vorteil in der Gesamtüberlebenszeit nach der Diagnosestellung gibt, zeigt sich statistisch kein signifikanter Unterschied (log-rank test, p = 0,33). 
